Clinical data shows distinct phases of progress: Initial Response (Weeks 1-4) Changes start within the first week
While this subtype is the less frequent (5% to 20% of all cases), its clinical impact is significant, since it can add prematurity to a foetus that has been developing in sub-optimal conditions if delivery becomes necessary
Core Thesis : The oral formulation removes injection barriers, potentially expanding the addressable patient population and helping Lilly capture additional market share against competitors
A randomized controlled trial showed that GLP-1RAs prevents the decline of cerebral metabolic rate for glucose (CMRglc) in AD, and GLP-1RAs may increase the expression of glucose transporters (e.g., GLUT1) at the blood-brain barrier (BBB) (Mullins et al., 2019)
Phase 1: Foundation (weeks 1 through 4 on GLP-1 medication) During the initial adjustment period, keep fiber supplementation simple and conservative